Question:Using Phoenix WinNonlin Crossover object for Tmax test [Nonparametrics]

posted by 0521 – China, 2018-11-09 06:02 (810 d 03:17 ago) – Posting: # 19550
Views: 6,424

Dear Helmut Schütz,

When using Phoenix WinNonlin Crossover object for Tmax testing, how can I judge whether it is equivalent by the result? :confused:

I read the "The Use Of Non-Parametric Methods In The Statistical Analysis" document (PMID: 4556704), and I think he is doing the following steps to judge:

1. Determine if the P value of the sequence is greater than 0.05,
2. If the P value of the sequence is less than 0.05, the test of "Treatment" cannot be performed.
3. If the P value of the sequence is greater than 0.05, it is judged whether the P value of the treatment is greater than 0.05.
4. If the P value of the Treatment is greater than the equivalent, otherwise it is not equivalent.

5. If the P value of the sequence and the P value of the Period are both greater than 0.05, a sign test can be used instead of the rank sum test used in the above steps.

Assuming α = 0.05, all of the above P values are the results in the "Effects" table.

Is the above judgment process correct? :confused:
If not, what is the correct judgment process? :confused:

PARAMETER  Test                                T_stat    L_stat   p_Value
Tmax       Sequence                            177.5              0.91791649
Tmax       Treatment|(SEQ1=SEQ2)                 220             0.021731156
Tmax       Period|(SEQ1=SEQ2)                    185              0.62428829
Tmax       Treatment & Residual (simultaneous)        5.6567621  0.059108471


[image]

Best,

0521

Complete thread:

Activity
 Admin contact
21,316 posts in 4,446 threads, 1,489 registered users;
online 6 (0 registered, 6 guests [including 2 identified bots]).
Forum time: Wednesday 09:20 UTC (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5